pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-758 |
Genomic Coordinates | chr14: 101026020 - 101026107 |
Synonyms | MIRN758, hsa-mir-758, MIR758 |
Description | Homo sapiens miR-758 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-758-5p | |||||||||||||||||||||||||||||||||||||||||||||
Sequence | 15| GAUGGUUGACCAGAGAGCACAC |36 | |||||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||||||||
Experiments | SOLiD | |||||||||||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
|||||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | GNG12 | ||||||||||||||||||||
Synonyms | - | ||||||||||||||||||||
Description | G protein subunit gamma 12 | ||||||||||||||||||||
Transcript | NM_018841 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on GNG12 | |||||||||||||||||||||
3'UTR of GNG12 (miRNA target sites are highlighted) |
>GNG12|NM_018841|3'UTR 1 TGGAATAGAGAAACAGCTCCTCGCCTCTTCCCAACAACGCAAATTATGAGCAGCTCCTTGAAGAGATTTACCTTCAGCTT 81 ATTTGGTAACCACTGCTAATAACTAAAATGTTCTCAGCTTGGAATAATGGACTCTGAAGTCTCTATTTTCCAAGTTGTCC 161 TTTCTCTTAAAATACCCTTTACTGATTTAATACAGAATAACAATCTTATTTTCCACTTGGTAACTATGGCTTTATGTTGG 241 GTTACTGTTTAAGGAAAGTTGATCTGGGCCTTTTTAAAAACATAATTATATACTTTAGAAATACAAGGGATTCCGATATG 321 TCAGGACCTAAATGGCCTAAGCACCTGTCAAATTAAAATTCCAAAATTCATTGAAATCCTAAAGCCTTGATATTATATTC 401 TTTATAAGGCGTGTGCCAGCCTGTATAGTATATAAGAGAGAGGGGTGTTTGTGTGTATATATATATGCCTTTGTGTATAC 481 ACTTATCAAAGCTATTTTCTTATGAAAACGTCCCTCTCTCCATACCATCAGTTTCTCAGTTCCAGAAGTTATACCTTTAT 561 TTTGAGCTGTGTATAGGTAGAATAAAAAATTCCTTTCATATCGTTATTGTACAAAAAGTAAAGAGTATCCTAAAGATTGT 641 ATTCATTGTAATCAAGTAATGCAATCATCTCTCCTCTCTTGAAATCTTGCTGGACCTCTTAGGCTACAATAAACTGTACC 721 AAACTAAACTGACAGTCCTTCGATAATATGAAACATTAATTTACAAGGACCCGTTAGGGCTTCAATGATGCTGAGTCTGG 801 AAAAGGGGAGGAGACCCTTGGGAGGACTCCAGGCAGCTGTGCTCCCAGGGCTCATGTTCTCTACTGGATTAGGGATAGGC 881 ACCTCTGAAATCTCCACCCTGATGATTGGAATGAAACGGAGTGAACATGAGCCCAGCTGAGAGAGGAGCAGGAATGTGTG 961 AAAAACAGCTGCTCTCCTTGTCCCAGCTTTGTGATTGAGCCCTCTGTCTTGCTCTCTCTGCCTTCCCTGTGTCTTTCTTC 1041 TCTTACCAGAGCATCTGTTTGCAGAGGTAACATTACCTTCCCCAGCCACAGGTATGTGGAATACGGTGAGGAAAAAAAAA 1121 ATTAAAAAAAAAATGCAAGCTGTCAGGATGCTTAAGCTCTTTTCAGACATCTGCAGTTTCATCCCTACCTTGTTCACATA 1201 CCATCCAAGAGGCACATAGGCTACCCAAGAGAGCCTTGGATTCAGTGGTACACTCCTTGGGCCCAAGGGCTTTAGCAGCT 1281 GGATATGGGGTTCCTTGATTTTCCTCTGGGCCCAAATATAGCCCTCACACTCTTGGAATTTCCAGGTATGGGGGTAGCCC 1361 CAAAAGGAGGAATCTCCTATGGCCAATAAGGTATCTTGACTTTATCAAAGTAGAAGAGAGGGTCACTTCGGAGTCAAATC 1441 ATACACTAGGCCTTTGATGCTTTAATTCTTCTTCAGTTCATTAAAAGTAACTACTAAGGAAAGGTTAAAAACTTCCCCTC 1521 AAAAAGGAATCAACCCCAGGAAGTAATTATTTACAACGATTTTCCCAAATTTTGTACAATCTGTCCTGGAAAGCAAACCC 1601 CTTTTAAAATCTAATGTCTGGGCTTTGAGTATTAGCTCATTTAGGGTGGACAAATGCATTACTGTTTTCAAACTGCTCAC 1681 ATTTATTCAGTATTTCTCCAAGTTGCTATCTACTCAGCCTTATGAATGCCCCTCGCTTTTCTAAGGCCATGTGAAAATCA 1761 CGGCACTGCCCTTAGCCTTGTGTCATCTGCTTTTTCGTTCTGCGATATGCCCAGTTCCCAAATCAATTATAGGTACCTGT 1841 TTAGGAGAGAGGAAGATTTTACCTCTCAAAGGGTGAGATTTGAAATTTACACTAAAAAGACAACTTTACATTTAATGCTT 1921 CACTTAATGAGACATTCTTTTTTTTATAAGTCTATTTTTCTACTCAGTTTCAGAACACTAATCTGATTTTCACTCTGATT 2001 TTTAACGTTTCTTTAAATATTTATAATGTAGCTTCTTTCAAAATATTTTCATGAAAAATTACTTTTATTATACCATTATG 2081 TGCATGTTATTGGTAGCAGGCATAGTTTATTATTTAGTACTGAAACATGCTCTTTTACCTAACAGTAAACAAGTATGTTT 2161 TGATATATATCTGTTAATATGCTTATAGTGGTAAGAAATGGACTTGAGGTCCCAGGAGATTTCATTTTATTCACCCTGGT 2241 CAGATACAATAAAGGCTATGAGTATAAATACATAACTTCCTAACCAGGTGTAGGGCATGTTCATGAATATCAAATCTTTT 2321 GATGCTGGACCCAAGAGAGGAAAAGTTGTAGCTAAATGTTGATTTACTTATAACTAGACGTCTATGTGAGAAAATATATG 2401 TATACATATATATGATATGCAGAAGTCACTTTTTTTATCAGGCTTTATTCTCCTTACAAAGCCACAGTTTAACTGTCTGC 2481 AACAGTTGGTTTATGTTAATGATAGACAAATACCCAGTGTTTGTTACTTTTTCCAACTACCACTGTAATGATAATCTTTC 2561 TCACGTATATACATGCAACTTCTTGGCTTCATTTCCATGAAGCTGTTTCAATATATTCAGTATACTTTGTCCTTAATGCT 2641 GCTTCTGTTAACAGTGATCTCTTTCTTTTTTTCATTCTTATATCTTCATTAGTTCATCATAAATCTGTCCAGTTGAGGCC 2721 TCAGGACCACGGCATGATTTCATGACTCCGAAGTATTTTACAGAAACATTTTTTAAATAAGGGAAATATTTTATATACCA 2801 GATGGTTCACAAGTGATGGCTCATAGCTAGTTTTTTTTTTTCTTCTAAAAAATGTCAGGTTTTTAAAATCATTTACCTTA 2881 TTAAAATGAAAAGTGCCATACTTAACTTTTAAAGGAAAGACCTGACTTGCTTTTTCTCTATTTAGACTGTTTTTGTACTT 2961 TACTAATCTTTAAACTATCAGGAAAAAAACCAAAACTTTATACCAATGATTTAGTAATTTTGAGGCATAGGGTAGCTTAC 3041 GTAGTGGAGGATGTGCCAAATATTCTCTTCAAATGCCACCTTCTCAATTTATAACTAAAATAGTGTTATCTGACTAATTC 3121 CTCTGAATTTTGATGTAAGATCTATATAGGCCCCCAAAATGATCGTAGTACATGCCAGTCATTTCTCAGTGAAATAAATA 3201 CAATACCAGAGTACATTATGGGTTTTATTGCTTTCTTTTATGGTAGACCTGTTAATGGGGAAAAAATACATCAAATCAAA 3281 TAGAATCTTATATCTGTATGTTAAAATAGAGCACTTACCTGAAGTCAGTGGCCTGGATCATAGCCCTGGATCATTTCCCA 3361 GTCTGTCCTGTGCTGTGTGACCTTGGACAAGGCGCTTCATCTCTCTGGGCCTCTATTTCTCCATTTGTAAAACAAGTGGC 3441 TGCAGTAGATGATGGCTGAGAGCCCTTCCTGTTCCCAGATGCCTTGGTCCAAAGACCCCACCCCTCTGCTGGTCCTGCCA 3521 ACGTGTTGGTGCTATAAGCTGCTTCAGATATAAAATTGGTTTATCTATAATGTTTGTTCATTTAATAGCTTCTAAAAGGC 3601 CTTTTTGTTATACAGTGCTTTTTTTCTAGTTTTATGGACTTGGTTACTGTAATAATGTCTTGTTTTTAGCCATGTAACTA 3681 CAAACAGATATTCTCTTGATGTCTTAGTAAATTTGCATTTGATATATCATTGATGAGATTTTGTTGTTATGTAATATTCT 3761 TTGGCTACGCATCTGTCCAGCATCTTATTAACCATAATACTGTGATCATTATTTGGAAATATGTCCTATGGAAAGAATAA 3841 AAGCATGTACTTCACAGCTAGCATGTTCACAGATTTGAAAGAAGTTTCATTAAAAGCACCATTGCTTTCTGTACTGCGTC 3921 AGTGCCTCATTGTATCATCCTACTTGTGTTTTGCTCAATAAATGAATAAAAGACCATTTCTCTTCAAAAAAAAAAAAAAA 4001 AAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Disease | 55970.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | MCF7 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000370982.3 | 3UTR | CAUCUUAUUAACCAUAAUACUGUGAUCAUUAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM714644 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000370982.3 | 3UTR | CAUCUUAUUAACCAUAAUACUGUGAUCAUUAUUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000370982.3 | 3UTR | CAUCUUAUUAACCAUAAUACUGUGAUCAUUAUUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
62 hsa-miR-758-5p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT085323 | MORC3 | MORC family CW-type zinc finger 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT089441 | STAMBP | STAM binding protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT089456 | TET3 | tet methylcytosine dioxygenase 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT111856 | CCND1 | cyclin D1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT184933 | ZNF268 | zinc finger protein 268 | ![]() |
![]() |
2 | 2 | ||||||
MIRT215288 | CREBRF | CREB3 regulatory factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT237300 | LPP | LIM domain containing preferred translocation partner in lipoma | ![]() |
![]() |
2 | 2 | ||||||
MIRT238446 | MYO10 | myosin X | ![]() |
![]() |
2 | 4 | ||||||
MIRT273827 | RPL41 | ribosomal protein L41 | ![]() |
![]() |
2 | 2 | ||||||
MIRT282703 | HOOK1 | hook microtubule tethering protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT347970 | ZNF850 | zinc finger protein 850 | ![]() |
![]() |
2 | 2 | ||||||
MIRT371076 | KLF3 | Kruppel like factor 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT464339 | USP6NL | USP6 N-terminal like | ![]() |
![]() |
2 | 2 | ||||||
MIRT470034 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT477506 | ELL2 | elongation factor for RNA polymerase II 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT482886 | CACNA2D3 | calcium voltage-gated channel auxiliary subunit alpha2delta 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT492606 | POLR3E | RNA polymerase III subunit E | ![]() |
![]() |
2 | 2 | ||||||
MIRT502294 | GNG12 | G protein subunit gamma 12 | ![]() |
![]() |
2 | 6 | ||||||
MIRT507600 | DCTN4 | dynactin subunit 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT510728 | SON | SON DNA binding protein | ![]() |
![]() |
2 | 6 | ||||||
MIRT514065 | KCNJ6 | potassium voltage-gated channel subfamily J member 6 | ![]() |
![]() |
2 | 8 | ||||||
MIRT519718 | ZNF512B | zinc finger protein 512B | ![]() |
![]() |
2 | 4 | ||||||
MIRT520890 | STRN | striatin | ![]() |
![]() |
2 | 2 | ||||||
MIRT521760 | PPIL1 | peptidylprolyl isomerase like 1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT526874 | ERCC8 | ERCC excision repair 8, CSA ubiquitin ligase complex subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT530232 | WSB2 | WD repeat and SOCS box containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT532003 | ACTR2 | ARP2 actin related protein 2 homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT533371 | UBE2D4 | ubiquitin conjugating enzyme E2 D4 (putative) | ![]() |
![]() |
2 | 4 | ||||||
MIRT547106 | PIGW | phosphatidylinositol glycan anchor biosynthesis class W | ![]() |
![]() |
2 | 2 | ||||||
MIRT548189 | FOXA1 | forkhead box A1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT552935 | VKORC1L1 | vitamin K epoxide reductase complex subunit 1 like 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT560085 | ZNF195 | zinc finger protein 195 | ![]() |
![]() |
2 | 2 | ||||||
MIRT561726 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | ![]() |
![]() |
2 | 2 | ||||||
MIRT562713 | ZNF415 | zinc finger protein 415 | ![]() |
![]() |
2 | 2 | ||||||
MIRT562761 | ZNF846 | zinc finger protein 846 | ![]() |
![]() |
2 | 2 | ||||||
MIRT564159 | ZNF117 | zinc finger protein 117 | ![]() |
![]() |
2 | 2 | ||||||
MIRT565673 | SETD5 | SET domain containing 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT565718 | SESN3 | sestrin 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566026 | RFX1 | regulatory factor X1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT569048 | ZNF655 | zinc finger protein 655 | ![]() |
![]() |
2 | 2 | ||||||
MIRT570367 | UBE2V1 | ubiquitin conjugating enzyme E2 V1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT570410 | TMEM189-UBE2V1 | TMEM189-UBE2V1 readthrough | ![]() |
![]() |
2 | 2 | ||||||
MIRT570443 | TMEM189 | transmembrane protein 189 | ![]() |
![]() |
2 | 2 | ||||||
MIRT571738 | RNF11 | ring finger protein 11 | ![]() |
![]() |
2 | 2 | ||||||
MIRT575042 | Tpgs2 | tubulin polyglutamylase complex subunit 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT614330 | ZDHHC22 | zinc finger DHHC-type containing 22 | ![]() |
![]() |
2 | 2 | ||||||
MIRT617629 | RAB3IP | RAB3A interacting protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT621667 | UBE4B | ubiquitination factor E4B | ![]() |
![]() |
2 | 2 | ||||||
MIRT639906 | SRGAP2 | SLIT-ROBO Rho GTPase activating protein 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT651436 | XRCC5 | X-ray repair cross complementing 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT683853 | ZNF208 | zinc finger protein 208 | ![]() |
![]() |
2 | 2 | ||||||
MIRT684841 | TPGS2 | tubulin polyglutamylase complex subunit 2 | ![]() |
![]() |
2 | 5 | ||||||
MIRT689347 | ZNF83 | zinc finger protein 83 | ![]() |
![]() |
2 | 2 | ||||||
MIRT692492 | SPIN4 | spindlin family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT695711 | OLA1 | Obg like ATPase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT698219 | TMEM248 | transmembrane protein 248 | ![]() |
![]() |
2 | 2 | ||||||
MIRT711560 | FAM20B | FAM20B, glycosaminoglycan xylosylkinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT712867 | TMEM67 | transmembrane protein 67 | ![]() |
![]() |
2 | 2 | ||||||
MIRT722956 | TSPAN1 | tetraspanin 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT723622 | SOBP | sine oculis binding protein homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT724176 | ABCF2 | ATP binding cassette subfamily F member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT755363 | LMBR1 | limb development membrane protein 1 | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|